Our STN: BLA 103792/5256

SUPPLEMENT BLA APPROVAL

October 29, 2010

Genentech Incorporated
Attention: Michelle H. Rohrer, Ph.D.
Vice President, Regulatory Affairs
1 DNA Way, MS#241B
South San Francisco, CA 94080

Dear Dr. Rohrer:

Please refer to your Supplemental Biologics License Application (sBLA), dated June 24, 2010, received June 25, 2010, submitted under section 351 of the Public Health Service Act for Herceptin (trastuzumab).

We acknowledge receipt of your amendments dated September 13 and 23, 2010 and October 8, 2010.

This “Changes Being Effected” labeling supplement to your biologics license application provides for revisions to the BOXED WARNING, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, USE IN SPECIFIC POPULATIONS, and PATIENT COUNSELING INFORMATION sections of the package insert to include additional information regarding fatal fetal pulmonary hypoplasia.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (package insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. For administrative purposes, please designate this submission “Product Correspondence – Final SPL for approved BLA STN 103792/5256.”
Also within 14 days, amend all pending supplemental applications for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

The SPL will be accessible via publicly available labeling repositories.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4) to the address above or by fax to 301-847-8444.

LETTERS TO HEALTH CARE PROFESSIONALS

Regarding the letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter) that you plan to issue, we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this BLA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993
**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Dr. Mona Patel, Regulatory Project Manager, at (301) 796-4236.

Sincerely,

/ Jeff Summers/
Jeff Summers, M.D.
Deputy Director for Safety
Division of Biologic Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

ENCLOSURE: Package Insert